Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05613764 · ClinicalTrials.gov registry record · NA
Message From Local Pharmacy Team
A NA study of COVID-19, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 520,000
- Enrollment target
- 1
- Study location
NCT05613764: Completed NA study of COVID-19, sponsored by University of Pennsylvania.
NCT05613764 is a NA study of COVID-19 that has completed, run by University of Pennsylvania. The registered enrollment target is 520,000 participants, above the 36,720-participant average among 298 other COVID-19 trials with a reported enrollment target (1316% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05613764, a NA study of COVID-19, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 520,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a control message telling patients that an updated COVID booster vaccine is waiting for them. The intervention testing if text messages encouraging vaccination that come from a patient's local pharmacy team will produce more vaccinations than otherwise identical messages.
Primary Outcome
Whether patients receive a bivalent COVID booster at the pharmacy in question
Conditions Studied
Interventions
- BEHAVIORAL COVID Booster text messages
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520,000 participants |
| Start Date | 2022-11-03 |
| Est. Completion | 2023-02-06 |
| Phase | NA |
What the finished NCT05613764 record still lists
NCT05613764 is an interventional study that assigns participants to a tested intervention. Its 520,000 participants enrollment target places it among the larger protocols in the corpus, above the 36,720-participant average among 298 other COVID-19 trials with a reported enrollment target (1316% higher).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which COVID Booster text messages is the first listed.
NCT05613764 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05613764 about?
NCT05613764 is a clinical study titled "Message From Local Pharmacy Team". This experiment is part of a megastudy with a total of ten experimental conditions and a holdout control condition to which patients will be randomly assigned. The focal comparison in this experiment is between a message encouraging vaccination that comes from a patient's local pharmacy team and a c...
What is the current status of trial NCT05613764?
This trial is currently completed. It is a NA study. The enrollment target is 520,000 participants. The study started on 2022-11-03. Estimated completion is 2023-02-06.
What conditions does trial NCT05613764 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05613764?
The interventions under investigation include: COVID Booster text messages (BEHAVIORAL).
Who is sponsoring clinical trial NCT05613764?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05613764 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05613764's enrollment target sits among peer trials
520,000 2nd of 298 the highest of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI